The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Here’s looking at you: CLL research to watch
Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the chronic lymphocytic leukemia (CLL) studies to watch out for in the lead-up to and beyond the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition. Dr Eichhorst highlights the FLAIR trial of ibrutinib-containing regimens, including ibrutinib and venetoclax, in the frontline setting (ISRCTN01844152). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
